Surface Oncology Overview
- Year Founded
-
2014
- Status
-
Acquired/Merged
- Employees
-
62
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$64.6M
- Investors
-
1
Surface Oncology General Information
Description
Surface Oncology Inc is a clinical-stage immuno-oncology company. It is developing new therapies that modify the spaces in and around tumors in the tumor microenvironment to create conditions that support and sustain anti-tumor immune responses. The company's pipeline products are SRF231, SRF373, SRF617, and SRF388. Geographically, the activities are carried out throughout the region of the United States.
Contact Information
Website
www.surfaceoncology.comCorporate Office
- 50 Hampshire Street
- 8th Floor
- Cambridge, MA 02139
- United States
Corporate Office
- 50 Hampshire Street
- 8th Floor
- Cambridge, MA 02139
- United States
Surface Oncology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 08-Sep-2023 | $64.6M | Completed | Generating Revenue | ||
| 6. Secondary Transaction - Open Market | Completed | Generating Revenue | ||||
| 5. IPO | 19-Apr-2018 | Completed | Clinical Trials - Phase 1 | |||
| 4. Early Stage VC | 11-Jan-2016 | Completed | Product Development | |||
| 3. Early Stage VC (Series A) | 21-Nov-2014 | Completed | Product Development | |||
| 2. Seed Round | 01-Jan-2014 | Completed | Product Development | |||
| 1. Accelerator/Incubator | Completed | Product Development |
Surface Oncology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Surface Oncology Comparisons
Industry
Financing
Details
Surface Oncology Competitors (27)
One of Surface Oncology’s 27 competitors is Sutro Biopharma, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sutro Biopharma | Formerly VC-backed | South San Francisco, CA | ||||
| Geron | Formerly VC-backed | Foster City, CA | ||||
| Autolus | Formerly VC-backed | London, United Kingdom | ||||
| aTyr Pharma | Formerly VC-backed | San Diego, CA | ||||
| Corvus Pharmaceuticals | Formerly VC-backed | South San Francisco, CA |
Surface Oncology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Surface Oncology Patents
Surface Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026101890-A1 | Combinations of anti-il-27 antibodies with toripalimab and bevacizumab | Pending | 05-Nov-2024 | ||
| WO-2026055168-A1 | Anti-il-27 antibodies and uses and doses thereof | Pending | 06-Sep-2024 | ||
| WO-2026055167-A1 | Anti-il-27 antibodies and use of biomarkers in uses thereof | Pending | 05-Sep-2024 | ||
| AU-2025262217-A1 | Methods for treating cancer using anti-ccr8 antibodies | Pending | 22-Apr-2024 | ||
| WO-2025226603-A1 | Methods for treating cancer using anti-ccr8 antibodies | Pending | 22-Apr-2024 | C07K16/2866 |
Surface Oncology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Surface Oncology Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Amgen Ventures | Corporate Venture Capital | Minority | ||
| Atlas Venture | Venture Capital | Minority | ||
| Eight Roads | Corporate Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| F-Prime | Venture Capital | Minority |
Surface Oncology ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.78 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Surface Oncology FAQs
-
When was Surface Oncology founded?
Surface Oncology was founded in 2014.
-
Where is Surface Oncology headquartered?
Surface Oncology is headquartered in Cambridge, MA.
-
What is the size of Surface Oncology?
Surface Oncology has 62 total employees.
-
What industry is Surface Oncology in?
Surface Oncology’s primary industry is Drug Discovery.
-
Is Surface Oncology a private or public company?
Surface Oncology is a Private company.
-
What is the current valuation of Surface Oncology?
The current valuation of Surface Oncology is .
-
What is Surface Oncology’s current revenue?
The current revenue for Surface Oncology is .
-
How much funding has Surface Oncology raised over time?
Surface Oncology has raised $313M.
-
Who are Surface Oncology’s investors?
Amgen Ventures, Atlas Venture, Eight Roads, , and F-Prime are 5 of 8 investors who have invested in Surface Oncology.
-
Who are Surface Oncology’s competitors?
Sutro Biopharma, Geron, Autolus, aTyr Pharma, and Corvus Pharmaceuticals are some of the 27 competitors of Surface Oncology.
-
When was Surface Oncology acquired?
Surface Oncology was acquired on 08-Sep-2023.
-
Who acquired Surface Oncology?
Surface Oncology was acquired by Coherus Oncology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
